The present invention relates to compounds which bind and/or inhibit prostate-specific membrane antigen (PSMA) comprising at least one group electron dense substituent (EDS), and at least one moiety which is amenable to radiolabeling; and therapeutic and diagnostic uses thereof.

Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

The invention relates to anti-PSMA antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modification having the effect of reducing FcRn binding is selected from positions His310, His433, His435, His436, Ile253. Antibodies of the present invention are particularly suited for use in radioimmunotherapy.

Disclosed are various methods and systems for increasing the permeability of cerebral capillaries. Increased permeability is accomplished via stretching means, inflaming means, overtaxing means, underoxygenating means, and/or immunocompromising means. Preferred stretching means include vasoconstrictors and cardiostimulators. Preferred inflaming means include electromagnetic fields and sonic waves. Preferred overtaxing means include xenon administration. Preferred underoxygenating means include airway-regulated oxygen deprivation. Preferred immunocompromising means include immunosuppressants and ionizing radiation. Also disclosed are processes for subsequently normalizing the permeability of cerebral capillaries. All disclosed means/processes can be selectively grouped, that is, combined or omitted, in accordance with the invention. By implementing the methods and systems invented, practitioners will be capable of opening (and closing) the blood-brain barrier, in which event therapeutic and diagnostic agents can enter the central nervous system and can act upon neurovascular-protected brain tissue.

The invention relates to amino acid and peptide conjugates, methods for making amino acid and peptide conjugates, conjugates produced by the methods, and pharmaceutical compositions comprising the conjugates. Methods of eliciting immune responses in a subject and methods of vaccinating a subject, uses of the conjugates for the same, and uses of the conjugates in the manufacture of medicaments for the same are also contemplated.

The invention relates to anti-CAIX antibodies comprising a heavy chain constant region comprising one or more amino acid substitutions compared to a wild-type IgG, wherein the one or more amino acid substitutions reduce the affinity of the antibody for the neonatal Fc receptor (FcRn), thereby reducing the serum half-life of the modified antibody compared to a wild-type antibody of class IgG. The one or more amino acid modification having the effect of reducing FcRn binding is selected from positions His310, His433, His435, His436, Ile253. Antibodies of the present invention are particularly suited for use in radioimmunotherapy.

Methods and formulations are provided for treating cancer and neoplastic diseases in conjunction with radiation therapy where such methods and formulations include a combination of a radiosensitizing agent that is metabolized by thymidine phosphorylase and a thymidine phosphorylase inhibitor that increases the half-life of the radiosensitizing agent.

The present invention regards specific IBAT inhibitors useful in the prophylaxis and/or treatment of a liver disease. It also relates to compositions comprising these IBAT inhibitors, a method for treatment of the disorders and a kit comprising the substances or the compositions.

Provided a method of sterilization by ultraviolet irradiation whereby effects on the human body can be mitigated and an odor that arises after ultraviolet irradiation can be controlled. The sterilization method includes: a step (a) of irradiating a skin of a hand or arm with ultraviolet having a wavelength of 200 nm or more and 230 nm or less; and a step (b) of applying a topical skin preparation, cosmetic, or aqueous solution containing at least one amino acid or amino acid derivative selected from an amino acid group A to a region of the skin irradiated with the ultraviolet. The amino acid group A includes valine, leucine, isoleucine, glutamic acid, arginine, serine, aspartic acid, proline, and glycine.

This disclosure provides IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof. In certain aspects the anti-IL-21 antibodies and fragments thereof can be hybridoma-derived murine monoclonal antibodies, and humanized versions thereof. In certain aspects the binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof provided herein inhibit, suppress, or antagonize IL-21 activity. In addition, this disclosure provides compositions and methods for diagnosing and treating diseases or disorders, e.g., inflammatory, immune-mediated, or autoimmune diseases or disorders associated with IL-21-mediated signal transduction. In a particular embodiment, the disclosure provides methods for treating or preventing Graft-versus-host disease (GVHD) using IL-21 binding molecules, e.g., anti-IL-21 antibodies and antigen-binding fragments thereof.